Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06589245
PHASE1

Inhaled Ciclesonide Study in Preterm Infants

Sponsor: Venkatesh Sampath

View on ClinicalTrials.gov

Summary

Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).

Official title: The Safety and Toxicity of Inhaled Ciclesonide (i.e., Alvesco) in Preterm Infants at Risk for Developing Bronchopulmonary Dysplasia

Key Details

Gender

All

Age Range

8 Days - 35 Days

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-09-16

Completion Date

2026-08-31

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

Alvesco Inhalant Product

Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.

Locations (1)

Children's Mercy Kansas City

Kansas City, Missouri, United States